

Resource Summary Report

Generated by SPARC SAWG on Aug 11, 2026

IgG

RRID:AB_2737665

Type: Antibody

Proper Citation

BD Biosciences Cat# 562581, RRID:AB_2737665

Antibody Information

URL: http://antibodyregistry.org/AB_2737665

Proper Citation: BD Biosciences Cat# 562581, RRID:AB_2737665

Target Antigen: IgG

Host Organism: mouse

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: IgG

Description: This monoclonal targets IgG

Target Organism: human

Clone ID: G18-145

Antibody ID: AB_2737665

Vendor: BD Biosciences

Catalog Number: 562581

Record Creation Time: 20250820T071729+0000

Record Last Update: 20250821T020057+0000

Ratings and Alerts

No rating or validation information has been found for IgG.

No alerts have been found for IgG.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Schoeberl UE, et al. (2025) Regulation of somatic hypermutation by higher-order chromatin structure. *Molecular cell*, 85(14), 2701.

Mantus GE, et al. (2025) Distinct binding modes drive the broad neutralization profile of two persistent influenza hemagglutinin stem-specific antibody lineages. *Structure (London, England : 1993)*, 33(5), 869.

Joyce MG, et al. (2025) Structural basis for complement receptor engagement and virus neutralization through Epstein-Barr virus gp350. *Immunity*, 58(2), 295.

Lederhofer J, et al. (2024) Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase. *Immunity*, 57(3), 574.

Yang YR, et al. (2024) Immune memory shapes human polyclonal antibody responses to H2N2 vaccination. *Cell reports*, 43(5), 114171.

Sutton MS, et al. (2023) Vaccine elicitation and structural basis for antibody protection against alphaviruses. *Cell*, 186(12), 2672.

Tauzin A, et al. (2023) Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine. *Cell reports*, 42(1), 111998.

Sannier G, et al. (2023) A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile. *Cell reports. Medicine*, 4(3), 100955.

Nicolas A, et al. (2023) An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells. *iScience*, 26(1), 105904.

Sangesland M, et al. (2022) Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus. *Immunity*, 55(9), 1693.

Wang S, et al. (2022) Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron. *Cell reports*, 39(8), 110862.

Moin SM, et al. (2022) Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses. *Immunity*, 55(12), 2405.

Tauzin A, et al. (2022) Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. *Cell host & microbe*, 30(1), 97.

Kaku Y, et al. (2021) Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. *Cell reports*, 36(2), 109385.

Mukhamedova M, et al. (2021) Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. *Immunity*, 54(4), 769.

Pušnik J, et al. (2021) Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help. *Cell reports*, 35(13), 109320.

Townsley SM, et al. (2021) B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. *Cell host & microbe*, 29(4), 564.

Zhou X, et al. (2021) Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. *Cell reports*, 35(6), 109109.

Anand SP, et al. (2021) Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. *Cell reports. Medicine*, 2(6), 100290.

Townsley SM, et al. (2021) Sequential staining of HIV gp140 to capture antigen-specific human B cells via flow cytometry. *STAR protocols*, 2(3), 100771.